BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tokushige K, Hyogo H, Nakajima T, Ono M, Kawaguchi T, Honda K, Eguchi Y, Nozaki Y, Kawanaka M, Tanaka S, Imajo K, Sumida Y, Kamada Y, Fujii H, Suzuki Y, Kogiso T, Karino Y, Munekage K, Kuromatsu R, Oeda S, Yanase M, Mori K, Ogawa Y, Seko Y, Takehara T, Itoh Y, Nakajima A, Kanemasa K, Nishino K, Masaki N, Takahashi H, Seike M, Torimura T, Saibara T, Toyota J, Chayama K, Hashimoto E. Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease and alcoholic liver disease: multicenter survey. J Gastroenterol 2016;51:586-96. [PMID: 26456168 DOI: 10.1007/s00535-015-1129-1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
Number Citing Articles
1 Ohki T, Kondo M, Karasawa Y, Kawamura S, Maeshima S, Kojima K, Seki M, Toda N, Shioda Y, Tagawa K. Evaluation of the Efficacy of Sorafenib on Overall Survival in Patients with Hepatocellular Carcinoma using FT Rate: A Devised Index. Adv Ther 2017;34:1097-108. [PMID: 28389996 DOI: 10.1007/s12325-017-0524-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
2 Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH, Zheng MH, Shiha G, Yilmaz Y, Gani R, Alam S, Dan YY, Kao JH, Hamid S, Cua IH, Chan WK, Payawal D, Tan SS, Tanwandee T, Adams LA, Kumar M, Omata M, George J. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14:889-919. [PMID: 33006093 DOI: 10.1007/s12072-020-10094-2] [Cited by in Crossref: 61] [Cited by in F6Publishing: 67] [Article Influence: 30.5] [Reference Citation Analysis]
3 Kawaguchi T, Tokushige K, Hyogo H, Aikata H, Nakajima T, Ono M, Kawanaka M, Sawada K, Imajo K, Honda K, Takahashi H, Mori K, Tanaka S, Seko Y, Nozaki Y, Kamada Y, Fujii H, Kawaguchi A, Takehara T, Yanase M, Sumida Y, Eguchi Y, Seike M, Yoneda M, Suzuki Y, Saibara T, Karino Y, Chayama K, Hashimoto E, George J, Torimura T. A Data Mining-based Prognostic Algorithm for NAFLD-related Hepatoma Patients: A Nationwide Study by the Japan Study Group of NAFLD. Sci Rep. 2018;8:10434. [PMID: 29992975 DOI: 10.1038/s41598-018-28650-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
4 Taniguchi M, Mizuno S, Yoshikawa T, Fujinami N, Sugimoto M, Kobayashi S, Takahashi S, Konishi M, Gotohda N, Nakatsura T. Peptide vaccine as an adjuvant therapy for glypican-3-positive hepatocellular carcinoma induces peptide-specific CTLs and improves long prognosis. Cancer Sci. 2020;111:2747-2759. [PMID: 32449239 DOI: 10.1111/cas.14497] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
5 Goossens N, Hoshida Y. Is Hepatocellular Cancer the Same Disease in Alcoholic and Nonalcoholic Fatty Liver Diseases? Gastroenterology 2016;150:1710-7. [PMID: 26784140 DOI: 10.1053/j.gastro.2016.01.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
6 Yatsuji S, Kotera Y, Kogiso T, Saito S, Omori A, Sagawa T, Taniai M, Shimizu K, Yamamoto M, Nakano M, Tokushige K. A case of hemorrhage of hepatocellular carcinoma resembling a hepatic cyst arising from non-cirrhotic steatohepatitis. Clin J Gastroenterol 2021;14:218-23. [PMID: 32979153 DOI: 10.1007/s12328-020-01251-z] [Reference Citation Analysis]
7 Uchida D, Takaki A, Adachi T, Okada H. Beneficial and Paradoxical Roles of Anti-Oxidative Nutritional Support for Non-Alcoholic Fatty Liver Disease. Nutrients 2018;10:E977. [PMID: 30060482 DOI: 10.3390/nu10080977] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
8 Fujii H, Kawada N, Japan Study Group Of Nafld Jsg-Nafld. The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2020;21:E3863. [PMID: 32485838 DOI: 10.3390/ijms21113863] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
9 Koyama N, Yamazaki T, Kanetsuki Y, Hirota J, Asai T, Mitsumoto Y, Mizuno M, Shima T, Kanbara Y, Arai S. Activation of apoptosis inhibitor of macrophage is a sensitive diagnostic marker for NASH-associated hepatocellular carcinoma. J Gastroenterol. 2018;53:770-779. [PMID: 29086016 DOI: 10.1007/s00535-017-1398-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
10 Ki Kim S, Ueda Y, Hatano E, Kakiuchi N, Takeda H, Goto T, Shimizu T, Yoshida K, Ikura Y, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Uemoto S, Chiba T, Ogawa S, Marusawa H. TERT promoter mutations and chromosome 8p loss are characteristic of nonalcoholic fatty liver disease-related hepatocellular carcinoma: Characteristics of genetic aberrations of hepatocellular carcinoma developed in nonalcoholic fatty liver disease. Int J Cancer 2016;139:2512-8. [DOI: 10.1002/ijc.30379] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
11 Ikejima K, Kon K, Yamashina S. Nonalcoholic fatty liver disease and alcohol-related liver disease: From clinical aspects to pathophysiological insights. Clin Mol Hepatol 2020;26:728-35. [PMID: 33053942 DOI: 10.3350/cmh.2020.0202] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
12 Kamada Y, Ono M, Hyogo H, Fujii H, Sumida Y, Yamada M, Mori K, Tanaka S, Maekawa T, Ebisutani Y, Yamamoto A, Takamatsu S, Yoneda M, Kawada N, Chayama K, Saibara T, Takehara T, Miyoshi E; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG‐NAFLD). Use of Mac-2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis. Hepatol Commun 2017;1:780-91. [PMID: 29404494 DOI: 10.1002/hep4.1080] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
13 Xiong J, Yin Z, Xu W, Shen Z, Li Y, Lu X. Alcoholic liver disease and risk of cholangiocarcinoma: a systematic review and meta-analysis. Onco Targets Ther 2018;11:8211-9. [PMID: 30538490 DOI: 10.2147/OTT.S184444] [Reference Citation Analysis]
14 Taida T, Arai M, Kanda T, Hige S, Ueno Y, Imazeki F, Izumi N, Tanaka E, Shinkai N, Yoshioka K, Nakamoto Y, Nishiguchi S, Tsuge M, Abe M, Sata M, Yatsuhashi H, Ido A, Kita K, Azemoto R, Kitsukawa Y, Goto N, Yokosuka O. The prognosis of hepatitis B inactive carriers in Japan: a multicenter prospective study. J Gastroenterol 2017;52:113-22. [PMID: 27306374 DOI: 10.1007/s00535-016-1229-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
15 Tobari M, Hashimoto E. Characteristic Features of Nonalcoholic Fatty Liver Disease in Japan with a Focus on the Roles of Age, Sex and Body Mass Index. Gut Liver 2020;14:537-45. [PMID: 31887811 DOI: 10.5009/gnl19236] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 13.0] [Reference Citation Analysis]
16 Inui S, Kondo H, Tanahashi Y, Fukukura Y, Sano K, Morisaka H, Saito K, Kondo F, Fukusato T, Furui S, Oba H. Steatohepatitic hepatocellular carcinoma: imaging findings with clinicopathological correlation. Clin Radiol 2021;76:160.e15-25. [PMID: 33046228 DOI: 10.1016/j.crad.2020.09.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Sumida Y, Yoneda M, Seko Y, Ishiba H, Hara T, Toyoda H, Yasuda S, Kumada T, Hayashi H, Kobayashi T, Imajo K, Yoneda M, Tada T, Kawaguchi T, Eguchi Y, Oeda S, Takahashi H, Tomita E, Okanoue T, Nakajima A, Japan Study Group Of Nafld Jsg-Nafld. Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Diagnostics (Basel) 2020;10:E579. [PMID: 32785100 DOI: 10.3390/diagnostics10080579] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
18 Li X, Wang X, Gao P. Diabetes Mellitus and Risk of Hepatocellular Carcinoma. Biomed Res Int. 2017;2017:5202684. [PMID: 29379799 DOI: 10.1155/2017/5202684] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
19 Tobari M, Hashimoto E, Taniai M, Kodama K, Kogiso T, Tokushige K, Yamamoto M, Takayoshi N, Satoshi K, Tatsuo A. The characteristics and risk factors of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis. J Gastroenterol Hepatol. 2020;35:862-869. [PMID: 31597206 DOI: 10.1111/jgh.14867] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
20 Anastasopoulos NT, Lianos GD, Tatsi V, Karampa A, Goussia A, Glantzounis GK. Clinical heterogeneity in patients with non-alcoholic fatty liver disease-associated hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2020;14:1025-33. [PMID: 32746645 DOI: 10.1080/17474124.2020.1802244] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
21 Taniai M, Hashimoto E, Tobari M, Kodama K, Tokushige K, Yamamoto M, Takayama T, Sugitani M, Sano K, Kondo F, Fukusato T. Clinicopathological investigation of steatohepatitic hepatocellular carcinoma: A multicenter study using immunohistochemical analysis of adenoma-related markers. Hepatol Res. 2018;48:947-955. [PMID: 30058778 DOI: 10.1111/hepr.13203] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
22 Isaac A, Mohamed SM, Ahmed OA, Hassan AGM, Rasmy HS. Amphiregulin as a novel diagnostic and prognostic biomarker of hepatocellular carcinoma before and after locoregional treatment. Egypt J Intern Med 2021;33. [DOI: 10.1186/s43162-021-00078-5] [Reference Citation Analysis]
23 Seto WK, Yuen MF. Nonalcoholic fatty liver disease in Asia: emerging perspectives. J Gastroenterol. 2017;52:164-174. [PMID: 27637587 DOI: 10.1007/s00535-016-1264-3] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 7.7] [Reference Citation Analysis]
24 Kodama K, Kawaguchi T, Hyogo H, Nakajima T, Ono M, Seike M, Takahashi H, Nozaki Y, Kawanaka M, Tanaka S, Imajo K, Sumida Y, Kamada Y, Fujii H, Seko Y, Takehara T, Itoh Y, Nakajima A, Masaki N, Torimura T, Saibara T, Karino Y, Chayama K, Tokushige K. Clinical features of hepatocellular carcinoma in nonalcoholic fatty liver disease patients without advanced fibrosis. Journal of Gastroenterology and Hepatology 2019;34:1626-32. [DOI: 10.1111/jgh.14608] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
25 Orci LA, Sanduzzi-Zamparelli M, Caballol B, Sapena V, Colucci N, Torres F, Bruix J, Reig M, Toso C. Incidence of Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00505-X. [PMID: 33965578 DOI: 10.1016/j.cgh.2021.05.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
26 Kogiso T, Tokushige K. The Current View of Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma. Cancers (Basel) 2021;13:516. [PMID: 33572797 DOI: 10.3390/cancers13030516] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
27 Kogiso T, Sagawa T, Kodama K, Taniai M, Hashimoto E, Tokushige K. Long-term outcomes of non-alcoholic fatty liver disease and the risk factors for mortality and hepatocellular carcinoma in a Japanese population. J Gastroenterol Hepatol 2020;35:1579-89. [PMID: 31975453 DOI: 10.1111/jgh.14989] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
28 Takeda H, Takai A, Inuzuka T, Marusawa H. Genetic basis of hepatitis virus-associated hepatocellular carcinoma: Linkage between infection, inflammation, and tumorigenesis. J Gastroenterol. 2017;52:26-38. [PMID: 27714455 DOI: 10.1007/s00535-016-1273-2] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 7.5] [Reference Citation Analysis]
29 Chitturi S, Wong VW, Chan WK, Wong GL, Wong SK, Sollano J, Ni YH, Liu CJ, Lin YC, Lesmana LA. The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups. J Gastroenterol Hepatol. 2018;33:86-98. [PMID: 28692197 DOI: 10.1111/jgh.13856] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 18.3] [Reference Citation Analysis]
30 Nagaoki Y, Hyogo H, Ando Y, Kosaka Y, Uchikawa S, Nishida Y, Teraoka Y, Morio K, Fujino H, Ono A, Nakahara T, Murakami E, Yamauchi M, Okamoto W, Kawaoka T, Tsuge M, Hiramatsu A, Miki D, Imamura M, Takahashi S, Chayama K, Aikata H. Increasing incidence of non-HBV- and non-HCV-related hepatocellular carcinoma: single-institution 20-year study. BMC Gastroenterol 2021;21:306. [PMID: 34332532 DOI: 10.1186/s12876-021-01884-5] [Reference Citation Analysis]
31 Nakatsuka T, Tateishi R, Koike K. Changing clinical management of NAFLD in Asia. Liver Int 2021. [PMID: 34459096 DOI: 10.1111/liv.15046] [Reference Citation Analysis]
32 Umemura A, Kataoka S, Okuda K, Seko Y, Yamaguchi K, Moriguchi M, Okanoue T, Itoh Y. Potential Therapeutic Targets and Promising Agents for Combating NAFLD. Biomedicines 2022;10:901. [DOI: 10.3390/biomedicines10040901] [Reference Citation Analysis]
33 Mahmoudi A, Butler AE, Jamialahmadi T, Sahebkar A. The role of exosomal miRNA in nonalcoholic fatty liver disease. J Cell Physiol 2022. [PMID: 35137416 DOI: 10.1002/jcp.30699] [Reference Citation Analysis]